コンポーネント:
治療オプション:
Fedorchenko Olga Valeryevna 、薬局による医学的評価、 最終更新日:28.03.2022
アテンション! そのこのページの情報は医療専門家のみを対象としています! その情報が収集したオープン源を含めることが可能である重大な誤差! 注意して、このページ上のすべての情報を再確認してください!
同じ成分を持つトップ20の薬:
⁇ стан ⁇ и。® 転移性去勢耐性前立腺癌(CRPC)患者の治療に適応されます。.
投薬情報。
⁇ стан ⁇ иの推奨用量は、1日1回経口投与される160 mg(40 mgカプセル)です。. ⁇ стан ⁇ иは、食事の有無にかかわらず服用できます。. 飲み込みカプセル全体。. カプセルを噛んだり、溶かしたり、開けたりしないでください。.
線量変更。
患者がグレード3以上の毒性または耐え難い副作用を経験した場合、1週間または症状がグレード2以下に改善するまで投与を保留し、必要に応じて同じまたは減量(120 mgまたは80 mg)で再開します。.
強力なCYP2C8阻害剤を併用。
強力なCYP2C8阻害剤の併用は、可能であれば避ける必要があります。. 患者に強力なCYP2C8阻害剤を同時投与する必要がある場合は、 ⁇ стан ⁇ иの用量を1日1回80 mgに減らします。. 強力な阻害剤の共同投与を中止した場合、 ⁇ стан ⁇ и用量は、強力なCYP2C8阻害剤の開始前に使用した用量に戻す必要があります。
.
強力なCYP3A4インデューサーの併用。
強力なCYP3A4インデューサーの併用は、可能であれば避けてください。. 患者に強力なCYP3A4インデューサーを同時投与する必要がある場合は、 ⁇ стан ⁇ иの用量を1日1回160 mgから240 mgに増やします。. 強力なCYP3A4インデューサーの同時投与を中止する場合、 ⁇ стан ⁇ и用量は、強力なCYP3A4インデューサーの開始前に使用した用量に戻す必要があります。.
妊娠。
⁇ стан ⁇ иは胎児への危害と妊娠の潜在的な損失を引き起こす可能性があります。.
WARNINGS
Included as part of the "PRECAUTIONS" Section
PRECAUTIONS
Seizure
Seizure occurred in 0.5% of patients receiving Кстанди in clinical studies. In these trials patients with predisposing factors for seizure were generally excluded. Seizure occurred from 31 to 603 days after initiation of Кстанди. Patients experiencing seizure were permanently discontinued from therapy and all seizure events resolved.
In a single-arm trial designed to assess the risk of seizure in patients with pre-disposing factors for seizure, 8 of 366 (2.2%) Кстанди-treated patients experienced a seizure. Three of the 8 patients experienced a second seizure during continued treatment with Кстанди after their first seizure resolved. It is unknown whether anti-epileptic medications will prevent seizures with Кстанди. Patients in the study had one or more of the following pre-disposing factors: the use of medications that may lower the seizure threshold (~ 54%), history of traumatic brain or head injury (~ 28%), history of cerebrovascular accident or transient ischemic attack (~ 24%), and Alzheimer’s disease, meningioma, or leptomeningeal disease from prostate cancer, unexplained loss of consciousness within the last 12 months, past history of seizure, presence of a space occupying lesion of the brain, history of arteriovenous malformation, or history of brain infection (all < 5%). Approximately 17% of patients had more than one risk factor.
Advise patients of the risk of developing a seizure while receiving Кстанди and of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others.
Permanently discontinue Кстанди in patients who develop a seizure during treatment.
Posterior Reversible Encephalopathy Syndrome (PRES)
There have been reports of posterior reversible encephalopathy syndrome (PRES) in patients receiving Кстанди. PRES is a neurological disorder which can present with rapidly evolving symptoms including seizure, headache, lethargy, confusion, blindness, and other visual and neurological disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI). Discontinue Кстанди in patients who develop PRES.
Patient Counseling Information
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION).
Seizure
- Inform patients that Кстанди has been associated with an increased risk of seizure. Discuss conditions that may predispose to seizures and medications that may lower the seizure threshold. Advise patients of the risk of engaging in any activity where sudden loss of consciousness could cause serious harm to themselves or others. Inform patients to contact their healthcare provider right away if they have loss of consciousness or seizure.
Posterior Reversible Encephalopathy Syndrome (PRES)
- Inform patients to contact their healthcare provider right away if they experience rapidly worsening symptoms possibly indicative of PRES such as seizure, headache, decreased alertness, confusion, reduced eyesight, or blurred vision.
Falls And Fall-Related Injuries
- Inform patients that Кстанди is associated with an increased incidence of dizziness/vertigo, falls, and fall-related injuries.
Hypertension
- Inform patients that Кстанди is associated with an increased incidence of hypertension.
Infections
- Inform patients that Кстанди may be associated with an increased incidence of infections. Advise patients to immediately contact their healthcare provider if they develop signs and symptoms of infection.
Dosing And Administration
- Inform patients receiving GnRH therapy that they need to maintain this treatment during the course of treatment with Кстанди.
- Instruct patients to take their dose at the same time each day (once daily). Кстанди can be taken with or without food. Each capsule should be swallowed whole. Do not chew, dissolve, or open the capsules.
- Inform patients that they should not interrupt, modify the dose, or stop Кстанди without first consulting their healthcare provider.
- Inform patients that if they miss a dose, then they should take it as soon as they remember. If they forget to take the dose for the whole day, then they should take their normal dose the next day. They should not take more than their prescribed dose per day.
Embryo-Fetal Toxicity
- Inform patients that Кстанди can be harmful to a developing fetus. Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose of Кстанди. Advise male patients to use a condom if having sex with a pregnant woman.
Nonclinical Toxicology
Carcinogenesis, Mutagenesis, Impairment Of Fertility
Long-term animal studies have not been conducted to evaluate the carcinogenic potential of enzalutamide.
Enzalutamide did not induce mutations in the bacterial reverse mutation (Ames) assay and was not genotoxic in either the in vitro mouse lymphoma thymidine kinase (Tk) gene mutation assay or the in vivo mouse micronucleus assay.
Based on nonclinical findings in repeat-dose toxicology studies, which were consistent with the pharmacological activity of enzalutamide, male fertility may be impaired by treatment with Кстанди. In a 26-week study in rats, atrophy of the prostate and seminal vesicles was observed at ≥ 30 mg/kg/day (equal to the human exposure based on AUC). In 4-, 13-, and 39-week studies in dogs, hypospermatogenesis and atrophy of the prostate and epididymides were observed at ≥ 4 mg/kg/day (0.3 times the human exposure based on AUC).
Use In Specific Populations
Pregnancy
Risk Summary
Кстанди is contraindicated for use in pregnant women because the drug can cause fetal harm and potential loss of pregnancy. Кстанди is not indicated for use in females. There are no human data on the use of Кстанди in pregnant women. In animal reproduction studies, oral administration of enzalutamide in pregnant mice during organogenesis caused adverse developmental effects at doses lower than the maximum recommended human dose (see Data).
Data
Animal Data
In an embryo-fetal developmental toxicity study in mice, enzalutamide caused developmental toxicity when administered at oral doses of 10 or 30 mg/kg/day throughout the period of organogenesis (gestational days 6-15). Findings included embryo-fetal lethality (increased post-implantation loss and resorptions) and decreased anogenital distance at ≥ 10 mg/kg/day, and cleft palate and absent palatine bone at 30 mg/kg/day. Doses of 30 mg/kg/day caused maternal toxicity. The doses tested in mice (1, 10 and 30 mg/kg/day) resulted in systemic exposures (AUC) approximately 0.04, 0.4 and 1.1 times, respectively, the exposures in patients. Enzalutamide did not cause developmental toxicity in rabbits when administered throughout the period of organogenesis (gestational days 6-18) at dose levels up to 10 mg/kg/day (approximately 0.4 times the exposures in patients based on AUC).
In a pharmacokinetic study in pregnant rats with a single oral 30 mg/kg enzalutamide administration on gestation day 14, enzalutamide and/or its metabolites were present in the fetus at a Cmax that was approximately 0.3 times the concentration found in maternal plasma and occurred 4 hours after administration.
Lactation
Risk Summary
Кстанди is not indicated for use in females. There is no information available on the presence of Кстанди in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Enzalutamide and/or its metabolites were present in milk of lactating rats (see Data).
Data
Following a single oral administration in lactating rats on postnatal day 14, enzalutamide and/or its metabolites were present in milk at a Cmax that was 4 times higher than concentrations in the plasma and occurred 4 hours after administration.
Females And Males Of Reproductive Potential
Contraception
Males
Based on findings in animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the final dose of Кстанди.
Infertility Based on animal studies, Кстанди may impair fertility in males of reproductive potential.
Pediatric Use
Safety and effectiveness of Кстанди in pediatric patients have not been established.
Geriatric Use
Of 1671 patients who received Кстанди in the two randomized placebo-controlled clinical trials, 75% were 65 and over, while 31% were 75 and over. No overall differences in safety or effectiveness were observed between these patients and younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Patients With Renal Impairment
A dedicated renal impairment trial for Кстанди has not been conducted. Based on the population pharmacokinetic analysis using data from clinical trials in patients with metastatic CRPC and healthy volunteers, no significant difference in enzalutamide clearance was observed in patients with pre-existing mild to moderate renal impairment (30 mL/min ≤ creatinine clearance [CrCL] ≤ 89 mL/min) compared to patients and volunteers with baseline normal renal function (CrCL ≥ 90 mL/min). No initial dosage adjustment is necessary for patients with mild to moderate renal impairment. Severe renal impairment (CrCL < 30 mL/min) and end-stage renal disease have not been assessed.
Patients With Hepatic Impairment
Dedicated hepatic impairment trials compared the composite systemic exposure of enzalutamide plus N-desmethyl enzalutamide in volunteers with baseline mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C, respectively) versus healthy controls with normal hepatic function. The composite AUC of enzalutamide plus N-desmethyl enzalutamide was similar in volunteers with mild, moderate, or severe baseline hepatic impairment compared to volunteers with normal hepatic function. No initial dosage adjustment is necessary for patients with baseline mild, moderate, or severe hepatic impairment.
The following is discussed in more detail in other sections of the labeling:
- Seizure
- Posterior Reversible Encephalopathy Syndrome (PRES)
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Three randomized clinical trials enrolled patients with metastatic prostate cancer that has progressed on androgen deprivation therapy (GnRH therapy or bilateral orchiectomy), a disease setting that is also defined as metastatic CRPC. Two trials were placebo-controlled (Studies 1 and 2), and one trial was bicalutamide-controlled (Study 3). In Studies 1 and 2, patients received Кстанди 160 mg or placebo orally once daily. In Study 3, patients received Кстанди 160 mg or bicalutamide 50 mg orally once daily. All patients continued androgen deprivation therapy. Patients were allowed, but not required, to take glucocorticoids.
The most common adverse reactions (≥ 10%) that occurred more commonly (≥ 2% over placebo) in the Кстанди-treated patients from the two randomized placebo-controlled clinical trials were asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.
Study 1: Кстанди versus Placebo in Metastatic CRPC Following Chemotherapy
Study 1 enrolled 1199 patients with metastatic CRPC who had previously received docetaxel. The median duration of treatment was 8.3 months with Кстанди and 3.0 months with placebo. During the trial, 48% of patients on the Кстанди arm and 46% of patients on the placebo arm received glucocorticoids.
Grade 3 and higher adverse reactions were reported among 47% of Кстанди-treated patients and 53% of placebo-treated patients. Discontinuations due to adverse events were reported for 16% of Кстанди-treated patients and 18% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was seizure, which occurred in 0.9% of the Кстанди-treated patients compared to none (0%) of the placebo-treated patients. Table 1 shows adverse reactions reported in Study 1 that occurred at a ≥ 2% higher frequency in the Кстанди arm compared to the placebo arm.
Table 1. Adverse Reactions in Study 1
Кстанди N = 800 | Placebo N = 399 | |||
Grade 1-4a (%) | Grade 3-4 (%) | Grade 1-4 (%) | Grade 3-4 (%) | |
General Disorders | ||||
Asthenic Conditionsb | 50.6 | 9.0 | 44.4 | 9.3 |
Peripheral Edema | 15.4 | 1.0 | 13.3 | 0.8 |
Musculoskeletal And Connective Tissue Disorders | ||||
Back Pain | 26.4 | 5.3 | 24.3 | 4.0 |
Arthralgia | 20.5 | 2.5 | 17.3 | 1.8 |
Musculoskeletal Pain | 15.0 | 1.3 | 11.5 | 0.3 |
Muscular Weakness | 9.8 | 1.5 | 6.8 | 1.8 |
Musculoskeletal Stiffness | 2.6 | 0.3 | 0.3 | 0.0 |
Gastrointestinal Disorders | ||||
Diarrhea | 21.8 | 1.1 | 17.5 | 0.3 |
Vascular Disorders | ||||
Hot Flush | 20.3 | 0.0 | 10.3 | 0.0 |
Hypertension | 6.4 | 2.1 | 2.8 | 1.3 |
Nervous System Disorders | ||||
Headache | 12.1 | 0.9 | 5.5 | 0.0 |
Dizzinessc | 9.5 | 0.5 | 7.5 | 0.5 |
Spinal Cord Compression and Cauda Equina Syndrome | 7.4 | 6.6 | 4.5 | 3.8 |
Paresthesia | 6.6 | 0.0 | 4.5 | 0.0 |
Mental Impairment Disordersd | 4.3 | 0.3 | 1.8 | 0.0 |
Hypoesthesia | 4.0 | 0.3 | 1.8 | 0.0 |
Infections And Infestations | ||||
Upper Respiratory Tract Infectione | 10.9 | 0.0 | 6.5 | 0.3 |
Lower Respiratory Tract And Lung Infectionf | 8.5 | 2.4 | 4.8 | 1.3 |
Psychiatric Disorders | ||||
Insomnia | 8.8 | 0.0 | 6.0 | 0.5 |
Anxiety | 6.5 | 0.3 | 4.0 | 0.0 |
Renal And Urinary Disorders | ||||
Hematuria | 6.9 | 1.8 | 4.5 | 1.0 |
Pollakiuria | 4.8 | 0.0 | 2.5 | 0.0 |
Injury, Poisoning And Procedural Complications | ||||
Fall | 4.6 | 0.3 | 1.3 | 0.0 |
Non-pathologic Fractures | 4.0 | 1.4 | 0.8 | 0.3 |
Skin And Subcutaneous Tissue Disorders | ||||
Pruritus | 3.8 | 0.0 | 1.3 | 0.0 |
Dry Skin | 3.5 | 0.0 | 1.3 | 0.0 |
Respiratory Disorders | ||||
Epistaxis | 3.3 | 0.1 | 1.3 | 0.3 |
a CTCAE v4 b Includes asthenia and fatigue. c Includes dizziness and vertigo. d Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention. e Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis. f Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection. |
Study 2: Кстанди Versus Placebo In Chemotherapy-Naive Metastatic CRPC
Study 2 enrolled 1717 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy, of whom 1715 received at least one dose of study drug. The median duration of treatment was 17.5 months with Кстанди and 4.6 months with placebo. Grade 3-4 adverse reactions were reported in 44% of Кстанди-treated patients and 37% of placebo-treated patients. Discontinuations due to adverse events were reported for 6% of Кстанди-treated patients and 6% of placebo-treated patients. The most common adverse reaction leading to treatment discontinuation was fatigue/asthenia, which occurred in 1% of patients on each treatment arm. Table 2 includes adverse reactions reported in Study 2 that occurred at a ≥ 2% higher frequency in the Кстанди arm compared to the placebo arm.
Table 2. Adverse Reactions in Study 2
Кстанди N = 871 | Placebo N = 844 | |||
Grade 1-4a (%) | Grade 3-4 (%) | Grade 1-4 (%) | Grade 3-4 (%) | |
General Disorders | ||||
Asthenic Conditionsb | 46.9 | 3.4 | 33.0 | 2.8 |
Peripheral Edema | 11.5 | 0.2 | 8.2 | 0.4 |
Musculoskeletal And Connective Tissue Disorders | ||||
Back Pain | 28.6 | 2.5 | 22.4 | 3.0 |
Arthralgia | 21.4 | 1.6 | 16.1 | 1.1 |
Gastrointestinal Disorders | ||||
Constipation | 23.2 | 0.7 | 17.3 | 0.4 |
Diarrhea | 16.8 | 0.3 | 14.3 | 0.4 |
Vascular Disorders | ||||
Hot Flush | 18.0 | 0.1 | 7.8 | 0.0 |
Hypertension | 14.2 | 7.2 | 4.1 | 2.3 |
Nervous System Disorders | ||||
Dizzinessc | 11.3 | 0.3 | 7.1 | 0.0 |
Headache | 11.0 | 0.2 | 7.0 | 0.4 |
Dysgeusia | 7.6 | 0.1 | 3.7 | 0.0 |
Mental Impairment Disordersd | 5.7 | 0.0 | 1.3 | 0.1 |
Restless Legs Syndrome | 2.1 | 0.1 | 0.4 | 0.0 |
Respiratory Disorders | ||||
Dyspneae | 11.0 | 0.6 | 8.5 | 0.6 |
Infections And Infestations | ||||
Upper Respiratory Tract Infectionf | 16.4 | 0.0 | 10.5 | 0.0 |
Lower Respiratory Tract And Lung Infectiong | 7.9 | 1.5 | 4.7 | 1.1 |
Psychiatric Disorders | ||||
Insomnia | 8.2 | 0.1 | 5.7 | 0.0 |
Renal And Urinary Disorders | ||||
Hematuria | 8.8 | 1.3 | 5.8 | 1.3 |
Injury, Poisoning And Procedural Complications | ||||
Fall | 12.7 | 1.6 | 5.3 | 0.7 |
Non-pathologic Fractures | 8.8 | 2.1 | 3.0 | 1.1 |
Metabolism and Nutrition Disorders | ||||
Decreased Appetite | 18.9 | 0.3 | 16.4 | 0.7 |
Investigations | ||||
Weight Decreased | 12.4 | 0.8 | 8.5 | 0.2 |
Reproductive System and Breast disorders | ||||
Gynecomastia | 3.4 | 0.0 | 1.4 | 0.0 |
a CTCAE v4 b Includes asthenia and fatigue. c Includes dizziness and vertigo. d Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention. e Includes dyspnea, exertional dyspnea, and dyspnea at rest. f Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis. g Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection. |
Study 3: Кстанди Versus Bicalutamide In Chemotherapy-Naive Metastatic CRPC
Study 3 enrolled 375 patients with metastatic CRPC who had not received prior cytotoxic chemotherapy, of whom 372 received at least one dose of study drug. The median duration of treatment was 11.6 months with Кстанди and 5.8 months with bicalutamide. Discontinuations with an adverse event as the primary reason were reported for 7.6% of Кстанди-treated patients and 6.3% of bicalutamide-treated patients. The most common adverse reactions leading to treatment discontinuation were back pain and pathological fracture, which occurred in 3.8% of Кстанди-treated patients for each event and in 2.1% and 1.6% of bicalutamide-treated patients, respectively. Table 3 shows overall and common adverse reactions (≥ 10%) in Кстанди-treated patients.
Table 3. Adverse Reactions in Study 3
Кстанди (N=183) | Bicalutamide (N=189) | |||
Grade 1-4a (%) | Grade 3-4 (%) | Grade 1-4a (%) | Grade 3-4 (%) | |
Overall | 94.0 | 38.8 | 94.2 | 37.6 |
General Disorders | ||||
Asthenic Conditionsb | 31.7 | 1.6 | 22.8 | 1.1 |
Musculoskeletal And Connective Tissue Disorders | ||||
Back Pain | 19.1 | 2.7 | 18.0 | 1.6 |
Musculoskeletal Painc | 16.4 | 1.1 | 14.3 | 0.5 |
Vascular Disorders | ||||
Hot Flush | 14.8 | 0 | 11.1 | 0 |
Hypertension | 14.2 | 7.1 | 7.4 | 4.2 |
Gastrointestinal Disorders | ||||
Nausea | 14.2 | 0 | 17.5 | 0 |
Constipation | 12.6 | 1.1 | 13.2 | 0.5 |
Diarrhea | 11.5 | 0 | 9.0 | 1.1 |
Infections And Infestations | ||||
Upper Respiratory Tract Infectiond | 12.0 | 0 | 6.3 | 0.5 |
Investigational | ||||
Weight Loss | 10.9 | 0.5 | 7.9 | 0.5 |
a CTCAE v 4 b Including asthenia and fatigue. c Including musculoskeletal pain and pain in extremity d Including nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis |
Laboratory Abnormalities
In the two randomized placebo-controlled clinical trials, Grade 1-4 neutropenia occurred in 15% of patients treated with Кстанди (1% Grade 3-4) and in 6% of patients treated with placebo (0.5% Grade 3-4). The incidence of Grade 1-4 thrombocytopenia was 6% of patients treated with Кстанди (0.3% Grade 3-4) and 5% of patients treated with placebo (0.5% Grade 3-4). Grade 1-4 elevations in ALT occurred in 10% of patients treated with Кстанди (0.2% Grade 3-4) and 16% of patients treated with placebo (0.2% Grade 3-4). Grade 1-4 elevations in bilirubin occurred in 3% of patients treated with Кстанди (0.1% Grade 3-4) and 2% of patients treated with placebo (no Grade 3-4).
Infections
In Study 1, 1% of patients treated with Кстанди compared to 0.3% of patients treated with placebo died from infections or sepsis. In Study 2, 1 patient in each treatment group (0.1%) had an infection resulting in death.
Falls And Fall-Related Injuries
In the two randomized placebo-controlled clinical trials, falls including fall-related injuries, occurred in 9% of patients treated with Кстанди compared to 4% of patients treated with placebo. Falls were not associated with loss of consciousness or seizure. Fall-related injuries were more severe in patients treated with Кстанди and included non-pathologic fractures, joint injuries, and hematomas.
Hypertension
In the two randomized placebo-controlled trials, hypertension was reported in 11% of patients receiving Кстанди and 4% of patients receiving placebo. No patients experienced hypertensive crisis. Medical history of hypertension was balanced between arms. Hypertension led to study discontinuation in < 1% of patients in each arm.
Post-Marketing Experience
The following additional adverse reactions have been identified during post approval use of Кстанди. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.
Body as a Whole: hypersensitivity (tongue edema, lip edema, and pharyngeal edema)
Gastrointestinal Disorders: vomiting
Neurological Disorders: posterior reversible encephalopathy syndrome (PRES)
Skin and Subcutaneous Tissue Disorders: rash
過剰摂取の場合は、 ⁇ стан ⁇ иによる治療を中止し、5.8日間の半減期を考慮して一般的な支援策を開始します。. 用量 ⁇ 増研究では、1日240 mg以下の発作は報告されていませんが、3回の発作が報告され、それぞれ360 mg、480 mg、600 mgが毎日報告されています。. 患者は、過剰摂取後に発作のリスクが高くなる可能性があります。.
心臓電気生理学QTc間隔での定常状態でのエンザルタミド160 mg /日の効果は、転移性CRPCの796人の患者で評価されました。大きな違いはありません(つまり.、20ミリ秒を超える)は、フリデリシア補正法に基づいて、 ⁇ стан ⁇ иで治療された患者のベースラインからの平均QT間隔の変化とプラセボで治療された患者の間に観察されました。. ただし、平均QTc間隔のわずかな増加(つまり、.、10ミリ秒未満)エンザルタミドによるものは、研究デザインの制限により除外できません。.
The pharmacokinetics of enzalutamide and its major active metabolite (N-desmethyl enzalutamide) were evaluated in patients with metastatic CRPC and healthy male volunteers. The plasma enzalutamide pharmacokinetics are adequately described by a linear two-compartment model with first-order absorption.
Absorption
Following oral administration (Кстанди 160 mg daily) in patients with metastatic CRPC, the median time to reach maximum plasma enzalutamide concentrations (Cmax) is 1 hour (range 0.5 to 3 hours). At steady state, the plasma mean Cmax values for enzalutamide and N-desmethyl enzalutamide are 16.6 μg/mL (23% CV) and 12.7 μg/mL (30% CV), respectively, and the plasma mean predose trough values are 11.4 μg/mL (26% CV) and 13.0 μg/mL (30% CV), respectively.
With the daily dosing regimen, enzalutamide steady state is achieved by Day 28, and enzalutamide accumulates approximately 8.3-fold relative to a single dose. Daily fluctuations in enzalutamide plasma concentrations are low (mean peak-to-trough ratio of 1.25). At steady state, enzalutamide showed approximately dose proportional pharmacokinetics over the daily dose range of 30 to 360 mg.
A single 160 mg oral dose of Кстанди was administered to healthy volunteers with a high-fat meal or in the fasted condition. A high-fat meal did not alter the AUC to enzalutamide or N-desmethyl enzalutamide. The results are summarized in Figure 1.
Distribution And Protein Binding
The mean apparent volume of distribution (V/F) of enzalutamide in patients after a single oral dose is 110 L (29% CV).
Enzalutamide is 97% to 98% bound to plasma proteins, primarily albumin. N-desmethyl enzalutamide is 95% bound to plasma proteins. In vitro, there was no protein binding displacement between enzalutamide and other highly protein bound drugs (warfarin, ibuprofen, and salicylic acid>) at clinically relevant concentrations.
Metabolism
Following single oral administration of 14C-enzalutamide 160 mg, plasma samples were analyzed for enzalutamide and its metabolites up to 77 days post dose. Enzalutamide, N-desmethyl enzalutamide, and a major inactive carboxylic acid metabolite accounted for 88% of the 14C-radioactivity in plasma, representing 30%, 49%, and 10%, respectively, of the total 14C-AUC0-inf.
In vitro, human CYP2C8 and CYP3A4 are responsible for the metabolism of enzalutamide. Based on in vivo and in vitro data, CYP2C8 is primarily responsible for the formation of the active metabolite (N-desmethyl enzalutamide). In vitro data suggest that carboxylesterase 1 metabolizes N-desmethyl enzalutamide and enzalutamide to the inactive carboxylic acid metabolite.
In vitro, N-desmethyl enzalutamide is not a substrate of human CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5.
Elimination
Enzalutamide is primarily eliminated by hepatic metabolism. Following single oral administration of 14C-enzalutamide 160 mg, 85% of the radioactivity is recovered by 77 days post dose: 71% is recovered in urine (including only trace amounts of enzalutamide and N-desmethyl enzalutamide), and 14% is recovered in feces (0.4% of dose as unchanged enzalutamide and 1% as N-desmethyl enzalutamide).
The mean apparent clearance (CL/F) of enzalutamide in patients after a single oral dose is 0.56 L/h (range 0.33 to 1.02 L/h).
The mean terminal half-life (t1/2) for enzalutamide in patients after a single oral dose is 5.8 days (range 2.8 to 10.2 days). Following a single 160 mg oral dose of enzalutamide in healthy volunteers, the mean terminal t1/2 for N-desmethyl enzalutamide is approximately 7.8 to 8.6 days.
However, we will provide data for each active ingredient